Clinical Trial Update: A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of insulin peglispro (LY2605541) for type 2 diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Peglispro (insulin peglispro)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: WITHDRAWN